Presentation is loading. Please wait.

Presentation is loading. Please wait.

Benjamin Wang MD 2/19/2015. Improving Lives one Bottle at a Time Non-Profit Founded in 2014 Scalable, Self-sustaining Recycling solution to: Address.

Similar presentations


Presentation on theme: "Benjamin Wang MD 2/19/2015. Improving Lives one Bottle at a Time Non-Profit Founded in 2014 Scalable, Self-sustaining Recycling solution to: Address."— Presentation transcript:

1 Benjamin Wang MD 2/19/2015

2

3

4 Improving Lives one Bottle at a Time Non-Profit Founded in 2014 Scalable, Self-sustaining Recycling solution to: Address Homelessness Create paid volunteer opportunities Provide affordable green housing Hand up for education/training

5 Purpose of Round 2 Still needs to work in 17 seconds Lead with your stronger slides Content: Much more than an investor pitch deck Must Make Sense Simple Wording Don’t read off your slides Don’t bad mouth your competition

6 Pitching and Jokes Personal elements draw the audience into the story Metaphor, Similes, Secrets, You Make the audience feel smart Give them a glimpse of what is coming up, tell them a story Surprise them Give them a something good to chew on Show them that you can bootstrap it Everything easy has been done We did that and here are the results What else can be done without funding

7 Judging Criteria Clarity (How it will make $) 1 pt- Unclear Summary 3 pt- Close but needs work 5 pt- Very Clear Viability (How likely it will make $) 1 pt- Little shown viability 3 pt- Close but needs work 5 pt- Strong Viability

8 Life and Healthcare Saving Innovations 8 Benjamin R. Wang MD CMO/Founder

9 Medical Device to prevent US Patent Filed (Oct 2013) 3 rd Generation Prototype Team Assembled Ventilator Associated Pneumonia (VAP) US Billion problem 9 Nevap Overview

10 10 Janet Kowalyski Harold Carrison Benjamin Wang MD Sandra Forrer Brenton Hanlon Team Regulatory Engineering Quality Assurance Founder/CMO CEO

11 11 50,000 US cases each year  300,000 US at risk/yr  Avr Treatment cost $40K Problematic Gold Standard: SSET tube Source: Center of Disease Control & Prevention

12 12 50,000 US cases each year  300,000 US at risk/yr  Avr Treatment cost $40K  No Medicare reimbursement  Growing Global ICU needs Problematic Gold Standard: SSET tube Source: Center of Disease Control & Prevention

13 13 50,000 US cases each year  300,000 US at risk/yr  Avr Treatment cost $40K  No Medicare reimbursement  Growing Global ICU needs  Era of Multi-antibiotic resistance “Superbugs” Problematic Gold Standard: SSET tube Source: Center of Disease Control & Prevention

14 Ventilator Associated Pneumonia Source: Medscape, Pubmed, Youtube.com

15

16 16 Simple & Effective Unique Low Risk Integratable Manufacturable Core Competencies Solution: Nevap Suction Line ET tube

17 Simple & Effective Unique Low Risk Integratable Manufacturable 17 Core Competencies Solution: Nevap Suction Line ET tube Class II Device, Predicate Devices needed only bench testing to gain FDA clearance.

18

19 19 “It just makes sense to Anesthesiologists” -Lynn White MD Anesthesiologist/CEO Patient Shield Concepts Testimonials & 3 rd Party Validation

20 20 “It just makes sense to Anesthesiologists” -Lynn White MD Anesthesiologist/CEO Patient Shield Concepts “When will this be available for clinical testing? I’ll write up a proposal” -Arash Esmailzadegan MD Anesthesiologist Testimonials & 3 rd Party Validation

21 21 “It just makes sense to Anesthesiologists” -Lynn White MD Anesthesiologist/CEO Patient Shield Concepts “When will this be available for clinical testing? I’ll write up a proposal” -Arash Esmailzadegan MD Anesthesiologist “If it can live up to its claims, this could help a lot of people,” -Jim Fink PhD Respiratory Industry Expert. Testimonials & 3 rd Party Validation

22 22 “It just makes sense to Anesthesiologists” -Lynn White MD Anesthesiologist/CEO Patient Shield Concepts “When will this be available for clinical testing? I’ll write up a proposal” -Arash Esmailzadegan MD Anesthesiologist “If it can live up to its claims, this could help a lot of people,” -Jim Fink PhD Respiratory Industry Expert. “This sounds very promising, when will we have more data in patients” -Mike Rosenthal MD Anesthesiologist/ Professor Emeritus Testimonials & 3 rd Party Validation

23 23 Competitive Devices

24 No Suction Blockage Regardless of patient movement Reinforced Suction Sealing Safely change tubes 24 Technology: Nevap Suction Line ET tube Patent Pending Technology 25 claims

25 No Suction Blockage Regardless of patient movement Reinforced Suction Sealing Safely change tubes Better Outcomes/Re-admissions Save Hospital $$$ Billions Decrease Legal Liability 25 Technology: Nevap Suction Line ET tube Patent Pending Technology 25 claims

26 No Suction Blockage Regardless of patient movement Reinforced Suction Sealing Safely change tubes Better Outcomes/Re-admissions Save Hospital $$$ Billions Decrease Legal Liability Lower rates of “Superbugs” Additional Device Applications 26 Technology: Nevap Suction Line ET tube Patent Pending Technology 25 claims

27

28 CovidienKimberly Clark TeleflexNevap Market Rank123 - Device Cost$40$43$40 Tbd Residual Secretions Border Suctioning Suction Blockage Rate Airway Sealing Mucosal harm Competitive Landscape Conservatively, estimate VAP reduction rates of 75% & US Hospital Savings of $9B/yr

29 350K Patients X $40/tube X 3.5used = $50M Nevap US TAM = $150M/yr 29 US VAP Market Opportunity Target Segment

30 350K Patients X $40/tube X 3.5used = $50M Nevap US TAM = $150M/yr 30 US VAP Market Opportunity Target Segment Key Decision Makers Anesthesiologists/Critical Care Nursing/Respiratory Therapy Hospital Administration

31 350K Patients X $40/tube X 3.5used = $50M Nevap US TAM = $150M/yr 31 US VAP Market Opportunity Target Segment Key Decision Makers Key Benefits Saves $Billions/ Better Outcomes Readily Integrated Increase Hospital Revenue Anesthesiologists/Critical Care Nursing/Respiratory Therapy Hospital Administration

32 Value Proposition (6 day ICU Stay) Gold Standard (1 tubes used) X $40= $40(purchase price) X $55= $55(Medicare reimbursement) Net Hospital Profit $15 VAP Risk Costs ($-5328) Incidence: 22.2/1000days X $40,000 average cost Nevap (2 tubes used) X $40= $80(purchase price) X $55= $110 (Medicare reimbursement) Net Hospital Profit $30 VAP Risk Costs ($-1200) Incidence: 5/1000days X $40,000 average cost Nevap New CPT Coding (2 tubes used) X $60= $120(purchase price) X $80= $160(Medicare reimbursement) Net Hospital Profit $40 VAP Risk Costs ($-1200) Incidence: 5/1000days X $40,000 average cost Hospital Profits $ 40 Hospital Savings $ 4128 Nevap Profit $ 102 TAM is now Triple $1.3B/yr Hospital Profits $ 15 Hospital Savings $ 0 Competition Profit $34 Hospital Profits $ 30 Hospital Savings $ 4128 Nevap Profit $ 68

33 Current Competition Profile Physician Bills One procedure Hospital Profits $ 15 Hospital Savings $ 0 Competition Profit $34

34 Nevap $40 Price Point Physician Bills One procedure Hospital Profits $ 15 Hospital Savings $ 0 Competition Profit $34 Physician Bills Two procedures Hospital Profits $ 30 Hospital Savings $ 4128 Nevap Profit $ 68

35 Nevap $60 Price Point Physician Bills One procedure Hospital Profits $ 15 Hospital Savings $ 0 Competition Profit $34 Physician Bills Two procedures Hospital Profits $ 40 Hospital Savings $ 4128 Nevap Profit $ 102 US TAM is $150M, Global Tam $450M

36

37 37 Strategic Manufacturing Partner Est. COG: <$2.00 (package, shipped) Low Capital Equipment Costs Rapid & Experienced OEM Expertise Existing Bioteq Distribution Rapid high precision scalability Licensing/Partnership for small market countries

38 1. Generate Independent Clinical Data through existing network of Academic physicians (UM, NYU, etc) Market Strategy: Promotion/Sales

39 1. Generate Independent Clinical Data through existing network of Academic physicians (UM, NYU, etc) 2. Target Anesthesia & Critical Care Groups through Publication, Medical Conferences, and Trade Shows Market Strategy: Promotion/Sales

40 1. Generate Independent Clinical Data through existing network of Academic physicians (UM, NYU, etc) 2. Target Anesthesia & Critical Care Groups through Publication, Medical Conferences, and Trade Shows 3. Target & Garner thought leader Endorsements Market Strategy: Promotion/Sales

41 1. Generate Independent Clinical Data through existing network of Academic physicians (UM, NYU, etc) 2. Target Anesthesia & Critical Care Groups through Publication, Medical Conferences, and Trade Shows 3. Target & Garner thought leader Endorsements 4. Apply for Unique CMS coding Market Strategy: Promotion/Sales

42 1. Generate Independent Clinical Data through existing network of Academic physicians (UM, NYU, etc) 2. Target Anesthesia & Critical Care Groups through Publication, Medical Conferences, and Trade Shows 3. Target & Garner thought leader Endorsements 4. Apply for Unique CMS coding 5. Target large hospital chains & distributorship for private labeling/licensing Market Strategy: Promotion/Sales

43 Beachhead sales Academic Researchers Promotional target price $10 / free US Business Strategy (sell on 10 unit basis) Est. COG: $2.00 (package, shipped) Gross Margins Est: 85+%

44 Beachhead sales Academic Researchers Promotional target price $10 / free Anesthesia Groups Promotional target price $40 US Business Strategy (sell on 10 unit basis) Est. COG: $2.00 (package, shipped) Gross Margins Est: 85+%

45 Beachhead sales Academic Researchers Promotional target price $10 / free Anesthesia Groups Promotional target price $40 Distributors Target price $60 US Business Strategy (sell on 10 unit basis) Est. COG: $2.00 (package, shipped) Gross Margins Est: 85+%

46 46 Milestones

47 Amounts in Millions Q2Q3Q4 Yr1Yr2Yr3Yr4Yr5 Sales Gross Margins Marketing Sales QA/Mfg Admin Total Exp EBITDA Financial Projections Break Even Profitability *Est. GM = 85+%

48 Ask $1M/20% equity ($350,000), PCT Filing$ 100K Pilot Run$ 250K IDE Study/Process Validation/ Quality Systems, Design History File, ($170,000) Biocomp Testing$ 100K Stability Testing$ 50K CE Mark$ 20K CMS Application, Stage II SBIR Grant, ($40,000) 510K $ 40K Legal/Accounting$ 40K Salaries$ 250K Business Dev$ 150K 48 Founders Funding to date: $60,000 Raised to date: $350,000 Completed Milestones Prototype US Patent Team Assembled Consultants Identified Manufacturing Partner

49 Nevap Suction Line Endotracheal Tube -Help hundreds of thousands US patients/yr -Saves US hospitals $Billions/yr 49 Summary 1.Functional Prototype, Patent Pending 2.Enormous Societal & Financial Returns 3.Key Team of Professionals 4.Physicians embrace design 5.Strong Incentives Benjamin R. Wang MD (408)

50

51 Questions?


Download ppt "Benjamin Wang MD 2/19/2015. Improving Lives one Bottle at a Time Non-Profit Founded in 2014 Scalable, Self-sustaining Recycling solution to: Address."

Similar presentations


Ads by Google